SWOT Analysis
- S
- W
- O
- T
-
Strength (6)
Growth in Net Profit with increasing Profit Margin (QoQ)
-
Weakness (8)
Declining ROCE
-
Opportunity (1)
FII / FPI or Institutions increasing their shareholding
-
Threats (2)
Stocks that are linked with ongoing investigations and legal cases, as a result of which investors should exercise caution. To set an alert for this, click here.
- Growth in Net Profit with increasing Profit Margin (QoQ)
- Companies with Low Debt
- Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
- Companies with Zero Promoter Pledge
- Decrease in Provision in recent results
- RSI indicating price strength
- FII / FPI or Institutions increasing their shareholding
Technical Analysis
Moving Averages
EMA
SMA
- 5 Day 1,166.0
- 10 Day 1,161.3
- 12 Day 1,161.3
- 20 Day 1,164.4
- 26 Day 1,168.4
- 50 Day 1,188.2
- 100 Day 1,216.4
- 200 Day 1,236.2
1,185.00
0.85%
Current Price
- Bullish Moving Averages 10
- Bearish Moving Averages 6
Resistance and support
1,191.53PIVOT
- First Resistance 1,201.0
- Second Resistance 1,216.9
- Third Resistance 1,226.4
- First Support 1,175.6
- Second Support 1,166.1
- Third Support 1,150.2
Company Financials
- Profit and loss statement
- Balance sheet
- Quarterly Result
- Ratio
- CAGR IN 10 YEARS
- 8.66%
- 10.19%
- 9.83%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 20,532.80 | 23,115.40 | 19,483.80 | 16,962.50 | 14,405.20 |
|
| Operating Profit | 3,917.40 | 7,381.80 | 5,926.40 | 4,214.80 | 2,594.10 |
|
| OP Profit Margin | 19.08 | 31.93 | 30.42 | 24.85 | 18.01 |
|
| Interest | 148.30 | 109.90 | 21.80 | 16.90 | 38.00 |
|
| Profit After Tax | 3,219.70 | 5,349.40 | 4,342.00 | 2,612.80 | 1,623.20 |
|
| Cash Profit | 4,585.10 | 6,502.70 | 5,361.30 | 3,557.20 | 2,453.80 |
|
| EPS | 38.56 | 64.14 | 260.31 | 156.83 | 97.55 |
|
- CAGR IN 10 YEARS
- 11.69%
- 10.40%
- 10.52%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Equity | 83.50 | 83.40 | 83.40 | 83.30 | 83.20 |
|
| Reserve Surplus | 31,463.60 | 28,999.60 | 24,157.40 | 20,517.80 | 18,413.10 |
|
| TOT Debts | 5,737.00 | 3,492.90 | 792.90 | 50.80 | 2,205.40 |
|
| Gross Block | 21,344.40 | 17,714.80 | 16,297.20 | 15,136.60 | 13,349.10 |
|
| Capital Work In Progress | 1,369.10 | 2,196.80 | 1,211.00 | 924.40 | 1,200.30 |
|
| Cash Liquid Investment | 1,957.60 | 976.80 | 1,216.90 | 645.80 | 2,030.50 |
|
| Net Working Capital | 9,044.20 | 7,869.20 | 8,487.20 | 4,733.80 | 7,738.90 |
|
| Current Assets | 15,486.60 | 13,714.50 | 13,793.10 | 9,490.50 | 12,020.50 |
|
| Current Liabilities | 6,442.40 | 5,845.30 | 5,305.90 | 4,756.70 | 4,281.60 |
|
Jun 2026 (CR) |
Mar 2026 (CR) |
Dec 2025 (CR) |
Sep 2025 (CR) |
Jun 2025 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 5,136.60 | 3,822.00 | 4,282.70 | 4,618.60 | 7,809.50 |
|
| Gross Profit | 814.70 | 13.00 | 418.50 | 811.10 | 4,216.10 |
|
| Gross Profit Margins | 74.58 | 70.66 | 75.09 | 78.15 | 85.46 |
|
| Operating Profit | 447.40 | -499.90 | 99.60 | 480.30 | 3,837.00 |
|
| OP Profit Margin | 11.10 | -6.57 | 3.40 | 11.90 | 50.65 |
|
| Interest | 73.10 | 54.30 | 41.40 | 33.40 | 19.20 |
|
| Profit After Tax | 404.70 | -219.40 | 90.60 | 387.30 | 2,961.20 |
|
| Cash Profit | 723.90 | 220.20 | 420.60 | 685.80 | 3,241.00 |
|
| EPS | 4.86 | -2.63 | 1.09 | 4.65 | 35.59 |
|
- CAGR IN 10 YEARS
- 11.69%
- 10.40%
- 10.52%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| PE | 32.52 | 17.85 | 23.65 | 29.46 | 44.14 |
|
| P/BV | 3.34 | 3.31 | 4.24 | 3.76 | 3.91 |
|
| MCAP Sales | 5.10 | 4.13 | 5.27 | 4.54 | 4.97 |
|
| Asset Turnover | 0.59 | 0.80 | 0.85 | 0.82 | 0.74 |
|
| EV/EBITDA | 19.35 | 11.69 | 15.06 | 15.89 | 23.35 |
|
| DEBT/EQUITY | 0.15 | 0.08 | 0.02 | 0.06 | 0.10 |
|
| ROE | 10.69 | 20.15 | 19.42 | 13.46 | 9.19 |
|
| ROCE | 12.59 | 25.47 | 25.40 | 18.82 | 11.63 |
|
Quick Results Snapshot
Q1FY27 Quarterly Result Announced for Dr. Reddy's Laboratories Ltd.
Pharmaceuticals company Dr. Reddy's Laboratories announced Q1FY27 results
Consolidated Financial Highlights:
- Total Revenue from operations for Q1FY27 stood at Rs 80,998 million, representing a 7.33% growth QoQ compared to Rs 75,464 million in Q4FY26, and a 5.51% decrease YoY from Rs 85,721 million in Q1FY26.
- Total income for Q1FY27 was reported at Rs 84,545 million, showing an increase of 5.40% QoQ from Rs 80,218 million in Q4FY26 and a decrease of 4.60% YoY from Rs 88,624 million in Q1FY26.
- Profit before tax for Q1FY27 reached Rs 5,533 million, a 177.07% increase QoQ from Rs 1,997 million in Q4FY26, while decreasing by 70.96% YoY from Rs 19,050 million in Q1FY26.
- Net profit for Q1FY27 was Rs 4,356 million, reflecting a growth of 96.84% QoQ from Rs 2,213 million in Q4FY26 and a 69.10% decline YoY compared to Rs 14,099 million in Q1FY26.
- Net profit attributable to equity shareholders of the parent company for Q1FY27 stood at Rs 4,443 million, representing a 101.13% increase QoQ from Rs 2,209 million in Q4FY26 and a 68.67% decrease YoY from Rs 14,181 million in Q1FY26.
- Basic and Diluted Earnings Per Share (EPS) for Q1FY27 was Rs 5.33, compared to Rs 2.65 in Q4FY26 and Rs 17.04/Rs 17.02 in Q1FY26.
- For the full year FY26, the Company reported total revenue from operations of Rs 3,37,002 million and a net profit of Rs 41,576 million.
- The Q1FY27 results were impacted by a provision of Rs 2,397 million towards inventory and other associated costs related to semaglutide's active pharmaceutical ingredient (API) being out of specification.
Standalone Financial Highlights:
- Total Revenue from operations for Q1FY27 was Rs 51,366 million, reflecting a growth of 34.39% QoQ from Rs 38,220 million in Q4FY26 and a decrease of 34.23% YoY from Rs 78,095 million in Q1FY26.
- Total income for the quarter stood at Rs 55,770 million, up 27.06% QoQ from Rs 43,892 million in Q4FY26 and down 32.05% YoY from Rs 82,078 million in Q1FY26.
- The Company reported a standalone Net Profit of Rs 4,047 million in Q1FY27, representing a turnaround from a loss of Rs 2,194 million in Q4FY26, but an 86.33% decline YoY from Rs 29,612 million in Q1FY26.
- Basic and Diluted EPS for Q1FY27 was Rs 4.86, compared to a negative Rs 2.63 in Q4FY26 and Rs 38.68 in Q1FY26.
Business Highlights:
- Segment Performance:
- Global Generics: This segment recorded a net revenue of Rs 71,993 million in Q1FY27, a growth of 9% QoQ from Rs 65,802 million and a 5% decline YoY from Rs 75,620 million.
- Pharmaceutical Services and Active Ingredients (PSAI): Revenue for Q1FY27 was Rs 10,527 million, down 5% QoQ from Rs 11,075 million and up 4% YoY from Rs 8,181 million.
- North America: Revenue for Q1FY27 was Rs 22,048 million (Rs 22.0 billion), a 35% YoY decline primarily due to lower Lenalidomide sales, but a 26% growth QoQ. During the quarter, the company launched six new products in the region.
- Emerging Markets: Revenue stood at Rs 18,328 million (Rs 18.3 billion), growing 31% YoY and 2% QoQ. Within this, Russia revenues reached Rs 9,000 million (Rs 9.0 billion), up 28% YoY.
- India: Revenue was Rs 17,177 million (Rs 17.2 billion) in Q1FY27, reflecting a growth of 17% YoY and 10% QoQ, driven by new brand launches and higher sales volumes.
- Europe: Revenue reached Rs 14,440 million (Rs 14.4 billion), an increase of 13% YoY, supported by new generic product launches.
- Product Launches: During Q1FY27, the company launched generic semaglutide injection in Canada and generic semaglutide tablets in India for the treatment of Type 2 diabetes.
- US Market Milestone: Achieved a first-to-market launch in the United States of Bosutinib Tablets 400mg with 180-days of generic drug exclusivity.
- Capital Expenditure: The Company’s capital expenditure for Q1FY27 stood at Rs 3,100 million (Rs 3.1 billion).
G V Prasad, Co-Chairman & MD, said: "Our Q1FY27 performance reflected the expected transition beyond lenalidomide revenues, along with an unexpected impact related to semaglutide AP!. However, our underlying base business continued to deliver healthy doubledigit growth across all key geographies. Our focus remains on improving the health of our base business through disciplined execution and operational excellence, while building our future pipeline of peptides, biosimilars, and innovative assets to deliver long-term growth."
Stocks Comparison
Table
Chart
Company name |
LTP |
Market cap (Cr) |
Return (1Y %) |
Risk (Std. Dev.) |
PE Ratio |
Financial Year |
|---|---|---|---|---|---|---|
| Dr Reddys Laboratories Ltd | 1,185.00 | 98,909.61 | -9.64 | 0.06 | 30.71 | Mar 2026 |
| Sun Pharmaceutical Industries Ltd | 1,837.30 | 440,829.81 | 13.40 | 0.05 | 36.35 | Mar 2026 |
| Divis Laboratories Ltd | 9,375.00 | 248,876.79 | 54.92 | 0.11 | 85.02 | Mar 2026 |
| Torrent Pharmaceuticals Ltd | 4,840.00 | 184,098.04 | 36.40 | 0.04 | 84.76 | Mar 2026 |
| Zydus Lifesciences Ltd | 1,160.00 | 115,710.44 | 12.21 | 0.07 | 25.04 | Mar 2026 |
| Cipla Ltd | 1,394.50 | 112,655.86 | -10.59 | 0.06 | 33.02 | Mar 2026 |
| Laurus Labs Ltd | 1,954.00 | 105,577.01 | 118.58 | 0.11 | 96.89 | Mar 2026 |
| Aurobindo Pharma Ltd | 1,734.00 | 99,770.53 | 58.26 | 0.04 | 26.90 | Mar 2026 |
| Lupin Ltd | 2,083.00 | 95,248.48 | 2.55 | 0.04 | 17.67 | Mar 2026 |
| Mankind Pharma Ltd | 2,300.70 | 95,029.28 | -10.49 | 0.06 | 46.30 | Mar 2026 |
| Glenmark Pharmaceuticals Ltd | 2,447.40 | 69,071.67 | 19.83 | 0.06 | 37.36 | Mar 2026 |
| Alkem Laboratories Ltd | 5,466.50 | 65,360.21 | -0.11 | 0.04 | 29.84 | Mar 2026 |
| Biocon Ltd | 385.00 | 62,743.22 | 8.65 | 0.08 | 150.39 | Mar 2026 |
| Abbott India Ltd | 27,270.00 | 57,948.75 | -11.95 | 0.05 | 35.89 | Mar 2026 |
| Anthem Biosciences Ltd | 928.50 | 52,305.97 | 7.40 | 0.09 | 91.36 | Mar 2026 |
| Ipca Laboratories Ltd | 2,009.60 | 50,984.40 | 53.26 | 0.07 | 37.10 | Mar 2026 |
| Gland Pharma Ltd | 2,961.90 | 48,874.56 | 49.07 | - | 43.30 | Mar 2026 |
| Glaxosmithkline Pharmaceuticals Ltd | 2,838.80 | 48,090.98 | 3.53 | 0.08 | 45.23 | Mar 2026 |
| Ajanta Pharma Ltd | 3,563.60 | 44,530.40 | 39.15 | 0.06 | 39.27 | Mar 2026 |
| J B Chemicals & Pharmaceuticals Ltd | 2,408.90 | 38,676.99 | 45.54 | 0.04 | 54.59 | Mar 2026 |
| Emcure Pharmaceuticals Ltd | 2,003.80 | 38,014.22 | 47.88 | 0.06 | 37.53 | Mar 2026 |
| Sai Life Sciences Ltd | 1,600.50 | 33,993.69 | 78.26 | 0.07 | 94.01 | Mar 2026 |
| Wockhardt Ltd | 2,086.10 | 33,897.49 | 34.74 | 0.17 | 81.91 | Mar 2026 |
| Neuland Laboratories Ltd | 22,840.00 | 29,303.47 | 41.37 | 0.12 | 58.96 | Mar 2026 |
| Acutaas Chemicals Ltd | 3,440.30 | 28,166.12 | 133.29 | 0.13 | 72.67 | Mar 2026 |
| Piramal Pharma Ltd | 208.16 | 27,713.34 | 2.48 | 0.10 | -88.14 | Mar 2026 |
| Granules India Ltd | 875.50 | 23,881.87 | 60.33 | 0.05 | 36.04 | Mar 2026 |
| Caplin Point Laboratories Ltd | 2,748.60 | 20,892.57 | 17.96 | 0.12 | 30.81 | Mar 2026 |
| Shilpa Medicare Ltd | 1,021.10 | 19,970.86 | 148.65 | 0.19 | 67.16 | Mar 2026 |
| ERIS Lifesciences Ltd | 1,321.30 | 18,311.01 | -19.85 | 0.05 | 27.50 | Mar 2026 |
| Pfizer Ltd | 4,002.40 | 18,310.07 | -23.07 | 0.06 | 24.90 | Mar 2026 |
| OneSource Specialty Pharma Ltd | 1,594.90 | 18,289.18 | -13.11 | 0.15 | -376.29 | Mar 2025 |
| Alivus Life Sciences Ltd | 1,430.80 | 17,566.14 | 52.37 | - | 29.13 | Mar 2026 |
| Jubilant Pharmova Ltd | 1,065.40 | 16,971.82 | -4.10 | 0.07 | 48.37 | Mar 2026 |
| Astrazeneca Pharma India Ltd | 6,751.50 | 16,878.75 | -26.12 | 0.07 | 99.50 | Mar 2026 |
| Cohance Lifesciences Ltd | 438.00 | 16,757.76 | -54.67 | - | 286.31 | Mar 2026 |
| Alembic Pharmaceuticals Ltd | 845.75 | 16,624.33 | -13.53 | 0.07 | 24.11 | Mar 2026 |
| Concord Biotech Ltd | 1,494.40 | 15,633.85 | -8.63 | - | 57.28 | Mar 2026 |
| Natco Pharma Ltd | 813.40 | 14,568.80 | -5.12 | 0.09 | 12.74 | Mar 2026 |
| Marksans Pharma Ltd | 320.15 | 14,508.04 | 78.62 | 0.14 | 27.81 | Mar 2026 |
| Strides Pharma Science Ltd | 1,219.80 | 11,243.23 | 37.79 | 0.07 | 17.72 | Mar 2026 |
| Viyash Scientific Ltd | 249.65 | 10,997.59 | 30.57 | 0.12 | 41.24 | Mar 2026 |
| Blue Jet Healthcare Ltd | 575.25 | 10,888.08 | -17.63 | 0.17 | 46.35 | Mar 2026 |
| Procter & Gamble Health Ltd | 5,503.50 | 9,135.47 | -13.42 | 0.08 | 25.59 | Mar 2026 |
| Aarti Pharmalabs Ltd | 820.40 | 7,439.37 | -10.67 | - | 34.91 | Mar 2026 |
| Sanofi India Ltd | 3,087.40 | 7,110.28 | -38.88 | 0.08 | 21.96 | Dec 2025 |
| Senores Pharmaceuticals Ltd | 1,402.60 | 6,459.48 | 103.50 | 0.10 | 49.48 | Mar 2025 |
| Jeena Sikho Lifecare Ltd | 510.40 | 6,344.31 | -39.09 | 0.11 | 26.81 | Mar 2026 |
Corporate Action
- Announcement
- Board Meeting
- Dividend
- Split
- Rights
- Events
Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015
Sep 18, 2026Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015
Dr. Reddy`s Laboratories Limited - News Verification
Sep 18, 2026The Exchange has sought clarification from Dr. Reddy`s Laboratories Limited with respect to recent news item captioned Dr Reddy s gets voluntary licence for Gilead s once-yearly HIV prevention drug. The response from the Company is attached.
Clarification sought from Dr Reddys Laboratories Ltd
Sep 17, 2026The Exchange has sought clarification from Dr Reddys Laboratories Ltd on September 17 2026 with reference to news appeared in https://pharma.economictimes.indiatimes.com/ dated September 17 2026 quoting "Dr Reddys gets voluntary licence for Gileads once-yearly HIV prevention drug"<BR><BR>The reply is awaited.
Dr. Reddy`s Laboratories Limited - News Verification
Sep 17, 2026The Exchange has sought clarification from Dr. Reddy`s Laboratories Limited with respect to recent news item captioned Dr Reddy s gets voluntary licence for Gilead s once-yearly HIV prevention drug. The response from the Company is awaited.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Sep 16, 2026Copies of newspaper publication
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015
Sep 11, 2026Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sep 10, 2026Intimation of Analyst meet
Dr. Reddy`s Laboratories Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Sep 10, 2026Dr. Reddy`s Laboratories Limited has informed the Exchange about Schedule of meet
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Aug 26, 2026Allotment of Employee Stock options
| Ex-Date | Purpose | Notes |
|---|---|---|
| 2026-07-22 | Quarterly Results | |
| 2026-05-12 | Audited Results | |
| 2026-01-21 | Quarterly Results | |
| 2025-10-24 | Quarterly Results | |
| 2025-07-23 | Quarterly Results | |
| 2025-05-09 | Audited Results, Dividend & Others | To consider other business matters. |
| 2025-01-23 | Quarterly Results | |
| 2024-11-05 | Quarterly Results | |
| 2024-07-27 | Quarterly Results & Stock Split | |
| 2024-05-07 | Audited Results & Final Dividend | |
| 2024-01-30 | Quarterly Results | |
| 2023-10-27 | Quarterly Results | |
| 2023-07-26 | Quarterly Results | |
| 2023-05-10 | Audited Results & Final Dividend | |
| 2023-01-25 | Quarterly Results | |
| 2022-10-28 | Quarterly Results | |
| 2022-07-28 | Quarterly Results | |
| 2022-05-19 | Audited Results & Final Dividend | |
| 2022-01-28 | Quarterly Results | |
| 2021-10-29 | Quarterly Results | |
| 2021-07-27 | Quarterly Results | |
| 2021-05-14 | Audited Results & Final Dividend | |
| 2021-01-29 | Quarterly Results | |
| 2020-10-28 | Quarterly Results | |
| 2020-07-29 | Quarterly Results | |
| 2020-05-20 | Audited Results & Final Dividend | (Revised) |
| 2020-05-13 | Audited Results & Final Dividend | |
| 2020-03-27 | Others | Inter alia, to consider and approve Raising of funds through issuance of Commercial Papers. |
| 2020-01-27 | Quarterly Results | |
| 2019-11-01 | Quarterly Results | |
| 2019-07-29 | Quarterly Results | |
| 2019-05-17 | Audited Results & Final Dividend | |
| 2019-02-01 | Quarterly Results | |
| 2018-10-26 | Quarterly Results | |
| 2018-07-26 | Quarterly Results | |
| 2018-05-22 | Audited Results & Dividend | |
| 2018-01-25 | Quarterly Results | |
| 2017-10-31 | Quarterly Results | |
| 2017-07-27 | Quarterly Results | |
| 2017-05-12 | Audited Results & Dividend | |
| 2017-02-04 | Quarterly Results | |
| 2016-10-25 | Quarterly Results | |
| 2016-07-26 | Quarterly Results | |
| 2016-05-12 | Audited Results & Dividend | |
| 2016-02-17 | Buy Back of Shares | |
| 2016-02-09 | Quarterly Results | |
| 2015-10-29 | Quarterly Results | |
| 2015-07-30 | Quarterly Results | |
| 2015-05-12 | Audited Results & Final Dividend | |
| 2015-01-29 | Quarterly Results | |
| 2014-10-29 | Quarterly Results | |
| 2014-07-30 | Quarterly Results | |
| 2014-05-13 | Audited Results & Dividend | |
| 2014-02-11 | Quarterly Results | |
| 2013-10-31 | Quarterly Results | |
| 2013-07-30 | Quarterly Results | |
| 2013-05-14 | Audited Results & Dividend | |
| 2013-02-14 | Quarterly Results | |
| 2012-10-30 | Quarterly Results | |
| 2012-07-19 | Quarterly Results | |
| 2012-05-11 | Audited Results & Dividend | |
| 2012-02-03 | Quarterly Results | |
| 2011-10-25 | Quarterly Results | |
| 2011-07-20 | Quarterly Results | |
| 2011-05-13 | Audited Results & Dividend | |
| 2011-01-25 | Quarterly Results | |
| 2010-10-23 | Quarterly Results | |
| 2010-07-22 | Quarterly Results | |
| 2010-05-06 | Audited Results, Dividend & ESOP | To grant of 16,800 stock options, exercisable at par value of Rs. 5/- to the Independent Directors of the Co. under "Dr. Reddy's ESOS, 2002" & "Dr. Reddy's Employees ADR Stock Option Scheme, 2007". |
| 2010-03-31 | Issuance of Bonus Debentures | For issuance of bonus debentures to Shareholders of the Co. from its General Reserves built from undistributed profits, The allotment of debentures will account for an amount not exceeding Rs. 520 Cr. |
| 2010-01-20 | Quarterly Results | |
| 2009-10-23 | Quarterly Results | |
| 2009-07-21 | Quarterly Results | |
| 2009-05-18 | Audited Results, Dividend & Others | To grant of 9,000 stock options, exercisable at par value of Rs 5/- to the Independent Directors of the Co. under "Dr. Reddy's ESOS 2002" & "Dr. Reddy's Employees ADR Stock Option Scheme, 2007". |
| 2009-01-20 | Quarterly Results | |
| 2008-10-23 | Quarterly Results & Amalgamation | To consider a Scheme of Amalgamation in terms of which Periecan Pharma Pvt. Ltd, a wholly owned subsidiary of the Company will be amalgamated with Dr. Reddy's Laboratories Ltd. |
| 2008-07-21 | Quarterly Results | |
| 2008-05-20 | Audited Results & Dividend | |
| 2008-01-25 | Quarterly Results | |
| 2007-10-24 | Quarterly Results | |
| 2007-07-23 | Quarterly Results | |
| 2007-05-18 | Audited Results & Dividend | |
| 2007-01-22 | Quarterly Results | |
| 2006-10-27 | Quarterly Results | |
| 2006-07-27 | Quarterly Results | |
| 2006-05-31 | Accounts & Dividend | |
| 2006-01-24 | Quarterly Results | |
| 2005-10-29 | Quarterly Results | |
| 2005-07-26 | Quarterly Results | |
| 2005-05-06 | Accounts & Dividend | |
| 2005-01-31 | Quarterly Results | |
| 2004-10-26 | Quarterly Results | |
| 2004-07-27 | Quarterly Results | |
| 2004-01-30 | Quarterly Results | |
| 2003-10-28 | Quarterly Results | |
| 2003-07-31 | Quarterly Results | |
| 2003-05-30 | Accounts & Dividend | |
| 2003-01-28 | Quarterly Results | |
| 2002-10-24 | Quarterly Results | |
| 2002-07-31 | Quarterly Results | |
| 2002-06-04 | Accounts & Dividend | |
| 2002-03-04 | Interim Dividend | |
| 2002-01-29 | Quarterly Results | |
| 2001-10-31 | Quarterly, H.Y. Results & I. Dividend | |
| 2001-07-31 | Quarterly Results & Others | Stock Split & Employees Stock Option Plan |
| 2001-05-30 | Accounts & Dividend | |
| 2001-01-30 | Quarterly Results | |
| 2000-10-30 | Quarterly Results | |
| 2000-07-28 | Quarterly Results | |
| 2000-03-23 | Interim Dividend and Issue of ADS | |
| 2000-03-06 | Merger | |
| 1999-10-20 | Quarterly Results | |
| 1999-07-29 | Quarterly Results | |
| 1999-04-19 | Accounts & Dividend | |
| 1999-01-30 | Quarterly Results | |
| 1998-10-21 | Quarterly Results | |
| 1998-04-27 | Accounts & Dividend | |
| 1997-05-17 | Accounts & Dividend. |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| 2026-07-10 | 8 | FINAL | 2026-07-10 | Equity Share |
| 2025-07-10 | 8 | FINAL | 2025-07-10 | Equity Share |
| 2024-07-16 | 40 | FINAL | Equity Share | |
| 2023-07-11 | 40 | FINAL | Equity Share | |
| 2022-07-11 | 30 | FINAL | Equity Share | |
| 2021-07-09 | 25 | FINAL | Equity Share | |
| 2020-07-13 | 25 | FINAL | Equity Share | |
| 2019-07-15 | 20 | FINAL | Equity Share | |
| 2018-07-16 | 20 | FINAL | Equity Share | |
| 2017-07-17 | 20 | FINAL | Equity Share | |
| 2016-07-18 | 20 | FINAL | Equity Share | |
| 2015-07-10 | 20 | FINAL | Equity Share | |
| 2014-07-11 | 18 | FINAL | Equity Share | |
| 2013-07-12 | 15 | FINAL | Equity Share | |
| 2012-06-28 | 13.75 | FINAL | Equity Share | |
| 2011-06-30 | 11.25 | FINAL | Equity Share | |
| 2010-07-02 | 11.25 | FINAL | Equity Share | |
| 2009-07-03 | 6.25 | FINAL | Equity Share | |
| 2008-07-04 | 3.75 | FINAL | Equity Share | |
| 2007-07-06 | 3.75 | FINAL | Equity Share | |
| 2006-07-07 | 5 | FINAL | Equity Share | |
| 2005-07-07 | 5 | FINAL | Equity Share | |
| 2004-07-13 | 5 | FINAL | Equity Share | |
| 2003-08-08 | 5 | FINAL | Equity Share |
| Ex-Date | Old FV | New FV | Record Date |
|---|---|---|---|
| 2024-10-28 | 5 | 1 | 2024-10-28 |
| 2001-10-10 | 10 | 5 | 2001-10-25 |
No Data Found
No Data Found
Insider & Institutional Activity
- Bulk Block Deals
- Insider Trading & SAST
Client name |
Deal Type |
Date |
Action |
Avg. price |
Quantity |
Exchange |
|---|---|---|---|---|---|---|
| Kapitalforeningen Investin Pro | Block | 2025-09-09 |
Purchase |
1,250.60 | 581,268 | NSE |
| Kapitalforeningen Pensam Invest | Block | 2025-09-09 |
Sell |
1,250.60 | 581,268 | NSE |
| The Mtbj Ltd. As Trst For Government Pension Investment Fund Mtbj400045849 | Block | 2025-07-14 |
Purchase |
1,254.00 | 141,606 | NSE |
| The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mtbj400045828 | Block | 2025-07-14 |
Sell |
1,254.00 | 141,606 | NSE |
| Bofa Securities Europe Sa | Block | 2024-03-26 |
Purchase |
6,184.85 | 260,000 | BSE |
| Bofa Securities Europe Sa | Block | 2024-03-26 |
Sell |
6,184.85 | 260,000 | BSE |
| The Jupiter Global Fund-Jupiter India Select | Block | 2024-01-18 |
Purchase |
5,645.45 | 31,907 | BSE |
| Jupiter South Asia Investment Company Limited | Block | 2024-01-18 |
Sell |
5,645.45 | 31,907 | BSE |
| Aia Vcc - Aia Asian Equity Fund | Block | 2023-10-26 |
Purchase |
5,355.20 | 20,271 | BSE |
| Aia Investment Trust-Aia Singapore Participating Fund Sgd | Block | 2023-10-26 |
Sell |
5,355.20 | 17,456 | BSE |
| Aia Investment Trust Aia Singapore Participating Fund Usd | Block | 2023-10-26 |
Sell |
5,355.20 | 1,551 | BSE |
| Aia Investment Trust Aia Singapore Participating Fund Heritage Usd | Block | 2023-10-26 |
Sell |
5,355.20 | 836 | BSE |
| Aia Investment Trust Aia Singapore Partcipating Fund Heritage Sgd | Block | 2023-10-26 |
Sell |
5,355.20 | 428 | BSE |
| Aia Vcc - Aia Asian Equity Fund | Block | 2023-10-19 |
Purchase |
5,656.20 | 41,157 | BSE |
| Aia Investment Trust - Aia Singapore Participating Fund Sgd | Block | 2023-10-19 |
Sell |
5,656.20 | 35,442 | BSE |
| Aia Investment Trust Aia Singapore Participating Fund Usd | Block | 2023-10-19 |
Sell |
5,656.20 | 3,149 | BSE |
| Aia Investment Trust Aia Singapore Participating Fund Heritage Usd | Block | 2023-10-19 |
Sell |
5,656.20 | 1,696 | BSE |
| Aia Investment Trust Aia Singapore Partcipating Fund Heritage Sgd | Block | 2023-10-19 |
Sell |
5,656.20 | 870 | BSE |
| Aia Vcc - Aia Asian Equity Fund | Block | 2023-10-11 |
Purchase |
5,563.00 | 96,120 | BSE |
| Aia International Limited | Block | 2023-10-11 |
Sell |
5,563.00 | 41,013 | BSE |
| Aia International Limited | Block | 2023-10-11 |
Sell |
5,563.00 | 19,410 | BSE |
| Aia Investment Trust-Aia Singapore Participating Fund Sgd | Block | 2023-10-11 |
Sell |
5,563.00 | 17,633 | BSE |
| Aia International Limited | Block | 2023-10-11 |
Sell |
5,563.00 | 9,894 | BSE |
| Aia International Limited | Block | 2023-10-11 |
Sell |
5,563.00 | 5,326 | BSE |
| Aia Investment Trust Aia Singapore Participating Fund Usd | Block | 2023-10-11 |
Sell |
5,563.00 | 1,567 | BSE |
| Aia Investment Trust Aia Singapore Participating Fund Heritage Usd | Block | 2023-10-11 |
Sell |
5,563.00 | 844 | BSE |
| Aia Investment Trust Aia Singapore Partcipating Fund Heritage Sgd | Block | 2023-10-11 |
Sell |
5,563.00 | 433 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-11-14 |
Purchase |
4,539.45 | 180,717 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-11-14 |
Sell |
4,539.45 | 180,717 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-11-03 |
Purchase |
4,555.65 | 180,718 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-11-03 |
Sell |
4,555.65 | 180,718 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-25 |
Purchase |
4,377.10 | 97,226 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-25 |
Sell |
4,377.10 | 97,226 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-17 |
Purchase |
4,310.80 | 152,789 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-17 |
Sell |
4,310.80 | 152,789 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-11 |
Purchase |
4,380.00 | 149,405 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-11 |
Sell |
4,380.00 | 149,405 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-03 |
Purchase |
4,335.70 | 149,492 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-03 |
Sell |
4,335.70 | 149,492 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-09-19 |
Purchase |
4,077.35 | 101,622 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-09-19 |
Sell |
4,077.35 | 101,622 | BSE |
| Ishares Msci India Etf | Block | 2022-08-08 |
Purchase |
4,156.85 | 137,595 | NSE |
| Ishares India 50 Etf | Block | 2022-08-08 |
Purchase |
4,156.85 | 19,329 | NSE |
| Ishares India Index Mauritius Company | Block | 2022-08-08 |
Sell |
4,156.85 | 137,595 | NSE |
| Ishares India Mauritius Co | Block | 2022-08-08 |
Sell |
4,156.85 | 19,329 | NSE |
| Ishares Msci India Etf | Block | 2022-07-25 |
Purchase |
4,373.50 | 137,594 | NSE |
| Ishares India 50 Etf | Block | 2022-07-25 |
Purchase |
4,373.50 | 19,328 | NSE |
| Ishares India Index Mauritius Company | Block | 2022-07-25 |
Sell |
4,373.50 | 137,594 | NSE |
| Ishares India Mauritius Co | Block | 2022-07-25 |
Sell |
4,373.50 | 19,328 | NSE |
| Ishares Msci India Etf | Block | 2022-07-18 |
Purchase |
4,546.00 | 138,419 | BSE |
| Ishares India 50 Etf | Block | 2022-07-18 |
Purchase |
4,546.00 | 19,328 | BSE |
| Ishares India Index Mauritius Company | Block | 2022-07-18 |
Sell |
4,546.00 | 138,419 | BSE |
| Ishares India Mauritius Co | Block | 2022-07-18 |
Sell |
4,546.00 | 19,328 | BSE |
| Ishares Core Msci Total International Stock Etf | Block | 2022-05-04 |
Purchase |
4,123.90 | 136,855 | BSE |
| Ishares Core Total International Stock Mauritius Co | Block | 2022-05-04 |
Sell |
4,123.90 | 136,855 | BSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-10-20 |
Purchase |
4,801.80 | 106,487 | BSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-10-20 |
Sell |
4,801.80 | 106,487 | BSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-10-11 |
Purchase |
4,849.20 | 106,487 | BSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-10-11 |
Sell |
4,849.20 | 106,487 | BSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-10-04 |
Purchase |
4,955.85 | 109,484 | NSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-10-04 |
Sell |
4,955.85 | 109,484 | NSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-09-23 |
Purchase |
4,846.35 | 108,390 | BSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-09-23 |
Sell |
4,846.35 | 108,390 | BSE |
| Ishares Msci All Country Asia Ex Japan Etf | Block | 2021-07-19 |
Purchase |
5,406.55 | 49,224 | BSE |
| Ishares All Country Asia Ex Japan Mauritius Co | Block | 2021-07-19 |
Sell |
5,406.55 | 49,224 | BSE |
| Ishares Msci All Country Asia Ex Japan Etf | Block | 2021-07-12 |
Purchase |
5,460.30 | 49,517 | BSE |
| Ishares All Country Asia Ex Japan Mauritius Co | Block | 2021-07-12 |
Sell |
5,460.30 | 49,517 | BSE |
| Ishares Emerging Markets Min Vol Factor Etf | Block | 2021-06-23 |
Purchase |
5,308.35 | 140,955 | BSE |
| Ishares Emerging Markets Minimum Volatility Mauritius Co | Block | 2021-06-23 |
Sell |
5,308.35 | 140,955 | BSE |
| Quaestio Solutions Funds | Block | 2021-06-16 |
Purchase |
5,414.90 | 28,916 | BSE |
| Quaestio Capital Management Sgr S.P.A.-Luxembourg Branch | Block | 2021-06-16 |
Sell |
5,414.90 | 28,916 | BSE |
| Ishares Emerging Markets Min Vol Factor Etf | Block | 2021-06-15 |
Purchase |
5,461.35 | 140,955 | BSE |
| Ishares Emerging Markets Minimum Volatility Mauritius Co | Block | 2021-06-15 |
Sell |
5,461.35 | 140,955 | BSE |
| Ishares Msci Emerging Markets Asia Etf | Block | 2021-04-22 |
Purchase |
5,156.75 | 20,773 | BSE |
| Ishares Em Asia Mauritius Co | Block | 2021-04-22 |
Sell |
5,156.75 | 20,773 | BSE |
| The Mtbj Ltd. As Trst For Government Pension Investment Fund Mtbj400045849 | Block | 2021-04-08 |
Purchase |
4,690.25 | 52,057 | BSE |
| The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mutb400045794 | Block | 2021-04-08 |
Sell |
4,690.25 | 52,057 | BSE |
| Vftr C Institutional Total International Stock Market Index Trust Ii | Block | 2021-03-04 |
Purchase |
4,483.75 | 29,859 | BSE |
| Vanguard Total International Stock Index Fund | Block | 2021-03-04 |
Sell |
4,483.75 | 29,859 | BSE |
| Vftr C Institutional Total International Stock Market Index Trust Ii | Block | 2021-02-25 |
Purchase |
4,435.80 | 35,447 | BSE |
| Vanguard Total International Stock Index Fund | Block | 2021-02-25 |
Sell |
4,435.80 | 35,447 | BSE |
| Vftr C Institutional Total International Stock Market Index Trust Ii | Block | 2021-02-04 |
Purchase |
4,639.85 | 38,389 | BSE |
| Vanguard Total International Stock Index Fund | Block | 2021-02-04 |
Sell |
4,639.85 | 38,389 | BSE |
| Vftr C Institutional Total International Stock Market Index Trust Ii | Block | 2021-01-28 |
Purchase |
4,882.00 | 33,851 | BSE |
| Vanguard Total International Stock Index Fund | Block | 2021-01-28 |
Sell |
4,882.00 | 33,851 | BSE |
| Vftr C Institutional Total International Stock Market Index Trust Ii | Block | 2021-01-14 |
Purchase |
5,283.80 | 34,374 | BSE |
| Vanguard Total International Stock Index Fund | Block | 2021-01-14 |
Sell |
5,283.80 | 34,374 | BSE |
| Vftr C Institutional Total International Stock Market Index Trust Ii | Block | 2020-12-03 |
Purchase |
4,846.35 | 33,373 | BSE |
| Vanguard Total International Stock Index Fund | Block | 2020-12-03 |
Sell |
4,846.35 | 33,373 | BSE |
| Vftr C Institutional Total International Stock Market Index Trust Ii | Block | 2020-11-13 |
Purchase |
4,818.75 | 35,555 | BSE |
| Vanguard Total International Stock Index Fund | Block | 2020-11-13 |
Sell |
4,818.75 | 35,555 | BSE |
| Vftr C Institutional Total International Stock Market Index Trust Ii | Block | 2020-10-28 |
Purchase |
5,080.10 | 36,043 | BSE |
| Vanguard Total International Stock Index Fund | Block | 2020-10-28 |
Sell |
5,080.10 | 36,043 | BSE |
| Vftr C Institutional Total International Stock Market Index Trust Ii | Block | 2020-10-15 |
Purchase |
5,117.95 | 36,209 | BSE |
| Vanguard Total International Stock Index Fund | Block | 2020-10-15 |
Sell |
5,117.95 | 36,209 | BSE |
| Vftr C Institutional Total International Stock Market Index Trust Ii | Block | 2020-09-30 |
Purchase |
5,079.05 | 38,268 | BSE |
| Vanguard Total International Stock Index Fund | Block | 2020-09-30 |
Sell |
5,079.05 | 38,268 | BSE |
| Bofa Securities Europe Sa | Block | 2020-08-05 |
Purchase |
4,634.85 | 38,882 | BSE |
| Merrill Lynch Markets Singapore Pte Ltd | Block | 2020-08-05 |
Sell |
4,634.85 | 38,882 | BSE |
| Trustees Of The Estate Of Bernice Pauahi Bishop Dba Kameham | Block | 2019-02-25 |
Purchase |
2,639.50 | 586,236 | NSE |
| Trustees Of The Estate Of Bernice Pauahi Bishop Dba Kameham | Block | 2019-02-25 |
Sell |
2,639.50 | 586,236 | NSE |
| Trustees Of The Estate Of Bernice Pauahi Bishop Dba Kameham | Block | 2019-02-18 |
Purchase |
2,563.35 | 570,529 | NSE |
| Trustees Of The Estate Of Bernice Pauahi Bishop Dba Kameham | Block | 2019-02-18 |
Sell |
2,563.35 | 570,529 | NSE |
| Dr.Reddy's Holdings Limited | Block | 2018-09-26 |
Purchase |
2,600.00 | 39,000 | BSE |
| Dr.Reddy's Holdings Limited | Block | 2018-09-26 |
Purchase |
2,600.00 | 39,000 | BSE |
| Venkateswara Prasad Gunupati | Block | 2018-09-26 |
Sell |
2,600.00 | 39,000 | BSE |
| Satish Reddy Kallam | Block | 2018-09-26 |
Sell |
2,600.00 | 39,000 | BSE |
| Dr.Reddy's Holdings Limited | Block | 2018-08-13 |
Purchase |
2,235.00 | 80,000 | BSE |
| Dr.Reddy's Holdings Limited | Block | 2018-08-13 |
Purchase |
2,235.00 | 80,000 | BSE |
| Venkateswara Prasad Gunupati | Block | 2018-08-13 |
Sell |
2,235.00 | 80,000 | BSE |
| Satish Reddy Kallam | Block | 2018-08-13 |
Sell |
2,235.00 | 80,000 | BSE |
| Merrill Lynch Markets Singapore Pte. Ltd. | Block | 2017-10-27 |
Purchase |
2,346.00 | 120,841 | BSE |
| Merrill Lynch Capital Markets Espana Sa Sv | Block | 2017-10-27 |
Sell |
2,346.00 | 120,841 | BSE |
| Dr.Reddy's Holdings Limited | Block | 2017-10-04 |
Purchase |
2,341.00 | 25,000 | BSE |
| Dr.Reddy's Holdings Limited | Block | 2017-10-04 |
Purchase |
2,340.00 | 25,000 | BSE |
| Venkateswara Prasad Gunupati | Block | 2017-10-04 |
Sell |
2,340.00 | 25,000 | BSE |
| Satish Reddy Kallam | Block | 2017-10-04 |
Sell |
2,341.00 | 25,000 | BSE |
| Dr.Reddy's Holdings Limited | Block | 2017-08-21 |
Purchase |
1,985.00 | 266,000 | BSE |
| Dr.Reddy's Holdings Limited | Block | 2017-08-21 |
Purchase |
1,985.00 | 140,500 | BSE |
| Satish Reddy Kallam | Block | 2017-08-21 |
Sell |
1,985.00 | 266,000 | BSE |
| Venkateswara Prasad Gunupati | Block | 2017-08-21 |
Sell |
1,985.00 | 140,500 | BSE |
| Dr.Reddy's Holdings Limited | Block | 2017-01-16 |
Purchase |
3,000.00 | 212,000 | BSE |
| Venkateswara Prasad Gunupati | Block | 2017-01-16 |
Sell |
3,000.00 | 212,000 | BSE |
| Dr.Reddy's Holdings Limited | Block | 2017-01-13 |
Purchase |
3,000.00 | 212,000 | BSE |
| Satish Reddy Kallam | Block | 2017-01-13 |
Sell |
3,000.00 | 212,000 | BSE |
| Dr Reddys Laboratories Limited | Bulk | 2016-06-16 |
Purchase |
3,076.83 | 884,213 | NSE |
| Ishares Bse Sensex Mauritius Company | Block | 2011-09-12 |
Purchase |
1,460.00 | 39,525 | NSE |
| The Royal Bank Of Scotland N.V | Block | 2011-09-12 |
Sell |
1,460.00 | 39,525 | NSE |
| The Bank Of New York Mellon Representative Office | Bulk | 2010-07-15 |
Purchase |
1,479.21 | 1,547,170 | NSE |
| Swiss Finance Corporation (Mauritius) Ltd | Block | 2010-01-14 |
Purchase |
1,245.00 | 50,295 | BSE |
| Citigroup Global Markets Mauritius Private Limited | Block | 2010-01-14 |
Sell |
1,245.00 | 50,295 | BSE |
| Credit Suisse (Singapore) Limited A/C Credit Suisse (Singapo | Block | 2010-01-13 |
Purchase |
1,211.00 | 50,295 | BSE |
| Citigroup Global Markets Mauritius Private Limited | Block | 2010-01-13 |
Sell |
1,211.00 | 50,295 | BSE |
Client name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Avg. Price |
Regulation (Insider/SAST) |
Mode |
|---|---|---|---|---|---|---|---|---|
| Icici Prudential Mutual Fund | Other |
Acquisition |
2026-08-26 | 712,884 | 42,045,639 | SAST 29(1) | Market | |
| Tricia Wetzel | Designated Person |
Acquisition |
2026-06-23 | 4,275 | 5,550 | 1,267.80 | Insider Trading | ESOP |
| Patrick Aghanian | Designated Person |
Acquisition |
2026-03-30 | 3,675 | 8,450 | 1,301.90 | Insider Trading | ESOP |
| Patrick Aghanian | Designated Person |
Acquisition |
2026-03-30 | 3,675 | 8,450 | 1,301.90 | Insider Trading | ESOP |
| Swarna Rallabandi | Designated Person |
Acquisition |
2026-03-16 | 4,000 | 4,000 | 1,325.50 | Insider Trading | ESOP |
| Zachary Mcclard | Designated Person |
Acquisition |
2026-02-19 | 1,200 | 1,200 | 1,269.60 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Acquisition |
2026-02-19 | 7,550 | 7,954 | 1,269.60 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Acquisition |
2026-02-19 | 7,550 | 7,954 | 1,269.60 | Insider Trading | ESOP |
| Zachary Mcclard | Designated Person |
Acquisition |
2026-02-19 | 1,200 | 1,200 | 1,269.60 | Insider Trading | ESOP |
| Tricia Wetzel | Designated Person |
Acquisition |
2025-12-11 | 4,275 | 4,275 | 1,267.15 | Insider Trading | ESOP |
| Life Insurance Corporation Of India | Other |
Acquisition |
2025-10-30 | 17,140,819 | 85,699,891 | SAST 29(2) | Market | |
| Vsd Family Trust & Pacs | Promoter |
Acquisition |
2025-10-03 | 171,726,540 | 222,305,640 | SAST 29(2) | Transfer | |
| Vsd Family Trust & Pacs | Promoter |
Acquisition |
2025-10-03 | 171,726,540 | 222,305,640 | SAST 29(1) | Transfer | |
| Patrick Aghanian | Designated Person |
Acquisition |
2025-09-17 | 4,775 | 4,775 | 1,316.40 | Insider Trading | ESOP |
| Patrick Aghanian | Designated Person |
Acquisition |
2025-09-17 | 4,775 | 4,775 | 1,316.40 | Insider Trading | ESOP |
| Anjum Swaroop | Designated Person |
Acquisition |
2025-09-02 | 10,495 | 19,605 | 1,260.80 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Disposal |
2025-08-04 | 7,450 | 404 | 1,292.10 | Insider Trading | Market Sale |
| Milan Kalawadia | Employee |
Acquisition |
2025-06-24 | 8,440 | 47,325 | 1,325.45 | Insider Trading | ESOP |
| Jeff Jorgenson | Employee |
Acquisition |
2025-06-24 | 1,495 | 3,965 | 1,325.45 | Insider Trading | ESOP |
| Milan Kalawadia | Employee |
Acquisition |
2025-06-24 | 8,440 | 47,325 | 1,325.45 | Insider Trading | ESOP |
| Jeff Jorgenson | Employee |
Acquisition |
2025-06-24 | 1,495 | 3,965 | 1,325.45 | Insider Trading | ESOP |
| Life Insurance Corporation Of India | Other |
Acquisition |
2025-06-20 | 16,789,472 | 68,559,072 | SAST 29(2) | Market | |
| Anjum Swaroop | Designated Person |
Acquisition |
2025-06-18 | 2,050 | 9,110 | 1,361.45 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Acquisition |
2025-06-18 | 7,625 | 7,854 | 1,361.49 | Insider Trading | ESOP |
| Lalitha Subramanian | Designated Person |
Acquisition |
2025-06-18 | 1,250 | 1,250 | 1,361.45 | Insider Trading | ESOP |
| Tricia Wetzel | Designated Person |
Acquisition |
2025-06-18 | 1,670 | 5,185 | 1,361.45 | Insider Trading | ESOP |
| Satish Reddy Kallam & Pacs | Promoter |
Acquisition |
2025-04-11 | 5,602,495 | 222,305,640 | SAST 29(2) | Transmission | |
| Satish Reddy Kallam | Promoter |
Pledge |
2024-12-24 | 746,500 | 746,500 | SAST Reg31 | Creation | |
| Satish Reddy Kallam | Promoter |
Pledge |
2024-12-24 | 746,500 | 746,500 | SAST Reg31 | Creation | |
| G. V. Prasadf | Promoter |
Pledge |
2024-12-24 | 622,080 | 622,080 | SAST Reg31 | Creation | |
| Satish Reddy Kallam | Promoter |
Pledge |
2024-12-24 | 746,500 | 0 | SAST Reg31 | Release | |
| G V Prasad | Promoter |
Pledge |
2024-12-24 | 622,080 | 0 | SAST Reg31 | Release | |
| G V Prasad | Promoter |
Pledge |
2024-12-24 | 318,100 | 318,100 | SAST Reg31 | Creation | |
| G V Prasad | Promoter |
Pledge |
2024-12-24 | 622,080 | 0 | SAST Reg31 | Release | |
| Satish Reddy Kallam | Promoter |
Pledge |
2024-12-24 | 746,500 | 0 | SAST Reg31 | Release | |
| G V Prasad | Promoter |
Pledge |
2024-12-24 | 50,000 | 268,100 | SAST Reg31 | Release | |
| G. V. Prasad | Promoter |
Pledge |
2024-12-24 | 268,100 | 0 | SAST Reg31 | Release | |
| C Swaminathan | Designated Person |
Disposal |
2024-09-26 | 1,700 | 46 | 6,651.41 | Insider Trading | Others |
| Vincent Colicchio | Designated Person |
Acquisition |
2024-09-26 | 1,594 | 10,935 | 6,553.00 | Insider Trading | ESOP |
| Anjum Swaroop | Designated Person |
Acquisition |
2024-09-26 | 1,412 | 1,412 | 6,553.00 | Insider Trading | ESOP |
| Tricia Wetzel | Designated Person |
Acquisition |
2024-09-04 | 594 | 703 | 6,802.78 | Insider Trading | ESOP |
| Sanjay Choubey | Designated Person |
Acquisition |
2024-09-04 | 215 | 263 | 6,914.00 | Insider Trading | ESOP |
| Bryan Dixon | Designated Person |
Acquisition |
2024-09-04 | 150 | 750 | 6,914.00 | Insider Trading | ESOP |
| Subba Inta | Designated Person |
Acquisition |
2024-09-04 | 704 | 1,671 | 6,914.00 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Acquisition |
2024-09-04 | 1,250 | 1,746 | 6,914.72 | Insider Trading | ESOP |
| Jeff Jorgenson | Designated Person |
Acquisition |
2024-09-04 | 474 | 784 | 6,914.00 | Insider Trading | ESOP |
| Juan Carlos Alvarez | Designated Person |
Acquisition |
2024-09-04 | 145 | 495 | 6,914.00 | Insider Trading | ESOP |
| Milan Kalawadia | Designated Person |
Acquisition |
2024-09-04 | 814 | 7,777 | 6,914.00 | Insider Trading | ESOP |
| Erez Israeli | KMP |
Acquisition |
2024-08-07 | 27,635 | 65,500 | 16,134.78 | Insider Trading | ESOP |
| Erez Israeli | KMP |
Disposal |
2024-08-07 | 65,500 | 0 | 6,711.43 | Insider Trading | Others |
| Life Insurance Corporation Of India | Other |
Acquisition |
2024-06-20 | 108,300 | 8,369,879 | SAST 29(1) | Market | |
| Sonal Shah | Designated Person |
Acquisition |
2024-06-20 | 136 | 592 | 6,095.10 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Acquisition |
2024-06-20 | 625 | 636 | 6,095.10 | Insider Trading | ESOP |
| K Satish Reddy & G V Prasad | Other |
Acquisition |
2024-05-27 | 34,345,308 | SAST 10(6) | - | ||
| Aps Trust | Promoter |
Disposal |
2024-05-27 | 34,345,308 | SAST 29(2) | Off Market / Inter se transfer | ||
| K Satish Reddy & Pacs | Promoter |
Acquisition |
2024-05-27 | 34,345,308 | 44,461,128 | SAST 29(2) | Off Market / Inter se transfer | |
| K Satish Reddy & G V Prasad | Promoter |
Acquisition |
2024-05-15 | 34,345,308 | SAST 10(5) | |||
| Jaya Lakshmi Ayyagari | Designated Person |
Acquisition |
2024-03-19 | 503 | 3,177 | 6,299.20 | Insider Trading | ESOP |
| Tricia N Wetzel | Designated Person |
Acquisition |
2024-03-19 | 1,550 | 2,650 | 6,299.20 | Insider Trading | ESOP |
| Keerthi Kandlikar | Designated Person |
Acquisition |
2024-03-19 | 80 | 985 | 6,299.20 | Insider Trading | ESOP |
| Uragasainareddy Medapati | Designated Person |
Acquisition |
2024-02-26 | 160 | 1,495 | 6,298.40 | Insider Trading | ESOP |
| John Roosenberg Ii | Designated Person |
Acquisition |
2024-02-26 | 175 | 175 | 6,298.40 | Insider Trading | ESOP |
| Mayank Nagar | Designated Person |
Acquisition |
2024-02-26 | 250 | 1,000 | 6,298.40 | Insider Trading | ESOP |
| Anjum Swaroop | Designated Person |
Disposal |
2024-02-13 | 3,744 | 0 | 6,092.86 | Insider Trading | Market Sale |
| Marc Kikuchi | Designated Person |
Acquisition |
2023-12-12 | 8,215 | 29,820 | 5,763.50 | Insider Trading | ESOP |
| Shobha Chagam | Designated Person |
Acquisition |
2023-12-12 | 230 | 2,649 | 5,763.50 | Insider Trading | ESOP |
| Life Insurance Corporation Of India | Other |
Disposal |
2023-11-30 | 3,391,906 | 9,328,967 | SAST 29(2) | Market | |
| Erez Israeli | KMP |
Acquisition |
2023-11-07 | 12,090 | 37,865 | 5,339.00 | Insider Trading | ESOP |
| Erez Israeli | KMP |
Disposal |
2023-11-01 | 5,000 | 25,775 | 5,327.45 | Insider Trading | Market Sale |
| C Swaminathan | Designated Person |
Disposal |
2023-09-19 | 2,000 | 11 | 5,817.00 | Insider Trading | Market Sale |
| Vanessa Brill | Designated Person |
Disposal |
2023-09-15 | 8,304 | 0 | 5,753.17 | Insider Trading | Market Sale |
| Life Insurance Corporation Of India | Other |
Disposal |
2023-09-13 | 3,424,110 | 12,720,873 | SAST 29(2) | Market | |
| Vanessa Brill | Designated Person |
Acquisition |
2023-09-07 | 8,304 | 8,304 | 5,661.15 | Insider Trading | ESOP |
| Vanessa Brill | Designated Person |
Acquisition |
2023-09-07 | 8,304 | 8,304 | 5,661.15 | Insider Trading | ESOP |
| Anjum Swaroop | Designated Person |
Acquisition |
2023-08-28 | 3,744 | 3,744 | 5,903.00 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Acquisition |
2023-08-28 | 875 | 2,011 | 5,903.00 | Insider Trading | ESOP |
| Sanjay Choubey | Designated Person |
Acquisition |
2023-08-28 | 215 | 480 | 5,903.00 | Insider Trading | ESOP |
| Tricia Wetzel | Designated Person |
Acquisition |
2023-08-28 | 1,175 | 5,338 | 5,903.00 | Insider Trading | ESOP |
| Tricia Wetzel | Designated Person |
Acquisition |
2023-08-28 | 1,175 | 5,338 | 5,903.00 | Insider Trading | ESOP |
| Anjum Swaroop | Designated Person |
Acquisition |
2023-08-28 | 3,744 | 3,744 | 5,903.00 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Acquisition |
2023-08-28 | 875 | 2,011 | 5,903.00 | Insider Trading | ESOP |
| Sanjay Choubey | Designated Person |
Acquisition |
2023-08-28 | 215 | 480 | 5,903.00 | Insider Trading | ESOP |
| Milan Kalawadia | Designated Person |
Acquisition |
2023-08-04 | 3,719 | 6,963 | 5,656.75 | Insider Trading | ESOP |
| Juan Carlos Alvarez | Designated Person |
Acquisition |
2023-08-04 | 350 | 350 | 5,656.75 | Insider Trading | ESOP |
| Erez Israeli | KMP |
Acquisition |
2023-08-03 | 197,165 | 227,940 | 5,650.00 | Insider Trading | ESOP |
| Erez Israeli | KMP |
Disposal |
2023-08-03 | 197,165 | 30,775 | 5,589.80 | Insider Trading | ESOP |
| David Moulton | Designated Person |
Acquisition |
2023-07-27 | 234 | 234 | 5,391.75 | Insider Trading | ESOP |
| Milan Kalawadia | Designated Person |
Acquisition |
2023-07-27 | 1,195 | 3,244 | 5,391.75 | Insider Trading | ESOP |
| Milan Kalawadia | Designated Person |
Acquisition |
2023-07-27 | 1,195 | 3,244 | 5,391.75 | Insider Trading | ESOP |
| David Moulton | Designated Person |
Acquisition |
2023-07-27 | 234 | 234 | 5,391.75 | Insider Trading | ESOP |
| Tricia Wetzel | Designated Person |
Acquisition |
2023-06-22 | 919 | 2,988 | 4,908.50 | Insider Trading | ESOP |
| Bryan Dixon | Designated Person |
Acquisition |
2023-06-22 | 225 | 600 | 4,908.50 | Insider Trading | ESOP |
| Jeff Jorgenson | Designated Person |
Acquisition |
2023-06-22 | 699 | 1,440 | 4,908.50 | Insider Trading | ESOP |
| Sunil Chebrolu | Designated Person |
Acquisition |
2023-06-22 | 484 | 5,288 | 4,908.50 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Acquisition |
2023-06-05 | 385 | 4,286 | 4,609.05 | Insider Trading | ESOP |
| Sanjay Choubey | Designated Person |
Acquisition |
2023-03-22 | 265 | 265 | 4,441.80 | Insider Trading | ESOP |
| Sanjay Choubey | Designated Person |
Acquisition |
2023-03-22 | 265 | 265 | 4,441.80 | Insider Trading | ESOP |
| Life Insurance Corporation Of India | Other |
Acquisition |
2023-03-13 | 3,361,696 | 16,144,983 | SAST 29(2) | Market & Encumbrance | |
| Tricia Wetzel | Designated Person |
Acquisition |
2022-12-19 | 2,420 | 2,519 | 4,478.05 | Insider Trading | ESOP |
| Vincent Colicchio | Designated Person |
Acquisition |
2022-12-19 | 1,260 | 1,260 | 4,478.05 | Insider Trading | ESOP |
| Milan Kalawadia | Designated Person |
Acquisition |
2022-12-19 | 2,411 | 16,593 | 4,478.05 | Insider Trading | ESOP |
| Jeff Jorgenson | Designated Person |
Acquisition |
2022-12-19 | 244 | 1,111 | 4,478.05 | Insider Trading | ESOP |
| Marc Kikuchi | Designated Person |
Acquisition |
2022-12-19 | 8,215 | 21,605 | 4,478.05 | Insider Trading | ESOP |
| Vanessa Brill | Designated Person |
Acquisition |
2022-10-28 | 1,470 | 5,373 | 4,442.35 | Insider Trading | ESOP |
| Erez Israeli | KMP |
Acquisition |
2022-10-10 | 30,785 | 30,785 | 4,398.70 | Insider Trading | ESOP |
| Life Insurance Corporation Of India | Other |
Acquisition |
2022-10-04 | 3,386,486 | 12,783,287 | SAST 29(2) | Market | |
| Mayank Nagar | Designated Person |
Acquisition |
2022-09-20 | 750 | 750 | 4,169.00 | Insider Trading | ESOP |
| Abhishek Mukhopadhyay | Designated Person |
Acquisition |
2022-09-20 | 540 | 1,830 | 4,169.00 | Insider Trading | ESOP |
| Sonal Shah | Designated Person |
Acquisition |
2022-09-20 | 456 | 456 | 4,169.00 | Insider Trading | ESOP |
| Anjum Swaroop | Designated Person |
Acquisition |
2022-09-20 | 338 | 6,660 | 4,169.00 | Insider Trading | ESOP |
| Uragasainareddy Medapati | Designated Person |
Acquisition |
2022-09-20 | 304 | 304 | 4,169.00 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Acquisition |
2022-08-01 | 875 | 3,901 | 4,212.00 | Insider Trading | ESOP |
| Jeff Jorgenson | Designated Person |
Acquisition |
2022-08-01 | 699 | 1,087 | 4,212.00 | Insider Trading | ESOP |
| Milan Kalawadia | Designated Person |
Acquisition |
2022-08-01 | 1,914 | 14,182 | 4,212.00 | Insider Trading | ESOP |
| Anjum Swaroop | Designated Person |
Acquisition |
2022-06-24 | 2,319 | 6,322 | 4,390.50 | Insider Trading | ESOP |
| Life Insurance Corporation Of India | Other |
Acquisition |
2022-06-17 | 3,332,456 | 9,396,801 | SAST 29(2) | Market | |
| Aps Trust | Promoter |
Acquisition |
2022-04-27 | 34,345,308 | 34,345,308 | Insider Trading | Scheme of Amalgamation/Merger/Demerger/Arrangement | |
| G Mallika Reddy | Promoter |
Acquisition |
2022-04-27 | 5,139 | 5,139 | Insider Trading | Scheme of Amalgamation/Merger/Demerger/Arrangement | |
| K Deepti Reddy | Promoter |
Acquisition |
2022-04-27 | 5,140 | 5,140 | Insider Trading | Scheme of Amalgamation/Merger/Demerger/Arrangement | |
| G V Sanjana Reddy | Promoter |
Acquisition |
2022-04-27 | 5,140 | 5,140 | Insider Trading | Scheme of Amalgamation/Merger/Demerger/Arrangement | |
| K Satish Reddy Huf | Promoter |
Acquisition |
2022-04-27 | 5,523,677 | 5,523,677 | Insider Trading | Scheme of Amalgamation/Merger/Demerger/Arrangement | |
| G.V. Prasad Huf | Promoter |
Acquisition |
2022-04-27 | 1,425,478 | 2,543,418 | Insider Trading | Scheme of Amalgamation/Merger/Demerger/Arrangement | |
| K Satish Reddy | Promoter & Director |
Acquisition |
2022-04-27 | 2,570 | 901,002 | Insider Trading | Scheme of Amalgamation/Merger/Demerger/Arrangement | |
| Samrajyam Reddy Kallam | Promoter |
Acquisition |
2022-04-27 | 5,139 | 1,120,499 | Insider Trading | Scheme of Amalgamation/Merger/Demerger/Arrangement | |
| Anuradha Gunupati | Promoter |
Acquisition |
2022-04-27 | 7,709 | 9,205 | Insider Trading | Scheme of Amalgamation/Merger/Demerger/Arrangement | |
| Dr. Reddy's Holdings Limited | Promoter |
Disposal |
2022-04-27 | 41,325,300 | 0 | Insider Trading | Scheme of Amalgamation/Merger/Demerger/Arrangement | |
| Anuradha Gunupati & Others | Promoter |
Acquisition |
2022-04-25 | 41,325,300 | 44,461,128 | SAST 29(2) | Scheme Of Amalgamation | |
| Anuradha Gunupati & Others | Promoter |
Acquisition |
2022-04-25 | 41,325,300 | 44,461,128 | SAST 29(1) | Scheme Of Amalgamation | |
| Life Insurance Corporation Of India | Other |
Acquisition |
2022-02-11 | 35,000 | 8,353,352 | SAST 29(1) | Market | |
| Marc Kikuchi | Designated Person |
Acquisition |
2021-12-21 | 7,015 | 13,390 | 4,608.48 | Insider Trading | ESOP |
| Vanessa Brill | Designated Person |
Acquisition |
2021-12-21 | 221 | 3,903 | 4,666.45 | Insider Trading | ESOP |
| Milan Kalawadia | Designated Person |
Acquisition |
2021-12-21 | 1,831 | 12,268 | 810.34 | Insider Trading | ESOP |
| Anjum Swaroop | Designated Person |
Acquisition |
2021-12-21 | 1,425 | 4,003 | 1,041.22 | Insider Trading | ESOP |
| Subba Inta | Employee |
Acquisition |
2021-12-21 | 309 | 967 | 4,801.73 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Acquisition |
2021-12-21 | 385 | 3,026 | 4,786.18 | Insider Trading | ESOP |
| C Swaminathan | Designated Person |
Disposal |
2021-10-04 | 489 | 2,641 | 4,822.44 | Insider Trading | Market Sale |
| Dr. Reddy's Employees Esos Trust | Trust |
Disposal |
2021-09-30 | 3,475 | 485,771 | 4,819.20 | Insider Trading | Off Market |
| Mukesh Rathi | Designated Person |
Acquisition |
2021-09-30 | 975 | 10,301 | 4,798.18 | Insider Trading | ESOP |
| V Narayana Reddy | Designated Person |
Acquisition |
2021-09-30 | 675 | 9,858 | 4,832.10 | Insider Trading | ESOP |
| Arun Prasad M S | Designated Person |
Acquisition |
2021-09-30 | 675 | 5,915 | 4,850.28 | Insider Trading | ESOP |
| P Yugandhar | Designated Person |
Acquisition |
2021-09-30 | 1,150 | 1,150 | 4,811.20 | Insider Trading | ESOP |
| Sanjay Sharma | Designated Person |
Disposal |
2021-09-29 | 1,000 | 2,179 | 4,910.00 | Insider Trading | Market Sale |
| Dr. Reddy's Employees Esos Trust | Trust |
Disposal |
2021-09-29 | 432 | 489,246 | 4,808.76 | Insider Trading | Off Market |
| Dr. Reddy's Employees Esos Trust | Trust |
Disposal |
2021-09-29 | 758 | 489,678 | 4,798.18 | Insider Trading | Market Sale |
| Sumit Kumar | Designated Person |
Disposal |
2021-09-29 | 309 | 81 | 4,768.60 | Insider Trading | ESOP |
| Sumit Kumar | Designated Person |
Acquisition |
2021-09-29 | 390 | 390 | 4,798.18 | Insider Trading | ESOP |
| Jerome Gnanaprakasam | Designated Person |
Disposal |
2021-09-29 | 449 | 1,002 | 4,768.60 | Insider Trading | ESOP |
| Jerome Gnanaprakasam | Designated Person |
Acquisition |
2021-09-29 | 800 | 1,451 | 4,798.18 | Insider Trading | ESOP |
| Arun Anand | Immediate Relative |
Disposal |
2021-09-27 | 300 | 215 | 4,790.00 | Insider Trading | Market Sale |
| Dr. Reddy's Employees Esos Trust | Trust |
Disposal |
2021-09-27 | 301 | 490,436 | 4,811.20 | Insider Trading | Off Market |
| Dr. Reddy's Employees Esos Trust | Trust |
Disposal |
2021-09-27 | 374 | 490,737 | 4,806.00 | Insider Trading | Market Sale |
| B. Mallikharjuna Rao | Designated Person |
Disposal |
2021-09-27 | 374 | 2,504 | 4,806.00 | Insider Trading | ESOP |
| B. Mallikharjuna Rao | Designated Person |
Acquisition |
2021-09-27 | 675 | 2,878 | 4,811.20 | Insider Trading | ESOP |
| Bijaygopal Chakrabarti | Designated Person |
Disposal |
2021-09-24 | 705 | 0 | 4,856.65 | Insider Trading | Market Sale |
| Abhishek Mukhopadhyay | Designated Person |
Acquisition |
2021-09-24 | 319 | 1,290 | 4,720.28 | Insider Trading | ESOP |
| Delores Mccreary | Designated Person |
Acquisition |
2021-09-24 | 229 | 229 | 4,569.70 | Insider Trading | ESOP |
| L Kalyanaraman | Designated Person |
Acquisition |
2021-09-24 | 278 | 2,675 | 4,526.23 | Insider Trading | ESOP |
| Anuj Reddy | Designated Person |
Acquisition |
2021-09-24 | 416 | 3,058 | 4,940.33 | Insider Trading | ESOP |
| Dr. Reddy's Employees Esos Trust | Trust |
Disposal |
2021-09-24 | 280 | 491,111 | 4,940.33 | Insider Trading | Off Market |
| Dr. Reddy's Employees Esos Trust | Trust |
Disposal |
2021-09-24 | 585 | 491,391 | 4,838.01 | Insider Trading | Market Sale |
| Anuj Reddy | Designated Person |
Disposal |
2021-09-24 | 585 | 2,642 | 4,838.01 | Insider Trading | ESOP |
| Anuj Reddy | Designated Person |
Acquisition |
2021-09-24 | 865 | 3,227 | 4,940.33 | Insider Trading | ESOP |
About Dr Reddys Laboratories Ltd
Stock PE (TTM)
30.71
Promoter Holding
26.64%
Book Value
456.1383
ROCE
13.65%
ROE
11.64%
Dr Reddy’s Laboratories Ltd. is an Indian multinational pharmaceutical company. It manufactures and markets a wide range of pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, and biologics. It was incorporated in 1984 with its headquarters in Hyderabad, Telangana. The company’s total income for the quarter ended June 2022 was Rs HYPERLINK "https://economictimes.indiatimes.com/dr-reddys-laboratories-ltd/stocks/companyid-13841.cms" 6,086.80 crore. On 5 August 2022, its market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/drreddyslaboratories/DRL" 69,190 crore.
The company is listed on the Bombay Stock Exchange with the code 500124 and on the National Stock Exchange with the code DRREDDY. It is also listed on the MCX Stock Exchange.
Dr Reddy’s Laboratories Ltd. has research and development centres and manufacturing facilities in 66 countries, with an employee strength of more than 24,000. For FY 2021-2022, the company’s profit after tax was Rs 2,182.50 crore, up 11.83% from FY 2020-2021. Its total assets for FY 2021-2022 stood at Rs 29,746.90 crore.
The company’s shareholding pattern on 30 June 2022 indicated a promoter stake of 26.71%, foreign institutional investor stake of 25.87%, domestic institutional investor stake of 25.19%, and public stake of 21.96%. The promoters have decreased holdings from 26.72% to 26.71% in the June 2022 quarter, while the mutual fund holdings have increased from 14.12% to 14.21%.
The company’s chairman is Mr K Satish Reddy. The co-chairman and managing director is Mr G V Prasad. The other board members include Mr Leo Puri, Ms Shikha Sharma, Dr Bruce L A Carter, Mr Allan Oberman, Mr Prasad R Menon, Ms Kalpana Morparia, and Mr Sridar Iyengar. The company’s auditors are S R Batliboi & Associates LLP.
On 5 August 2022, Dr Reddy’s Laboratories Ltd.’s share price on BSE closed at Rs 4154. Its NSE share price closed at Rs 4,156.85. The company’s 52-week high share price was Rs 5,077, and the 52-week low was Rs 3,654.
As of July 2022, the company’s mutual fund holdings included Franklin India Pension Plan, Aditya Birla SL Equity Hybrid ‘95 Fund, Franklin India Debt Hybrid Fund, and ICICI Prudential Regular Savings Fund with 1.04%, 0.79%, 0.62%, and 0.60% stake, respectively.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.
Dr Reddys Laboratories share price as on 21 Sep 2026 is Rs. 1185. Over the past 6 months, the Dr Reddys Laboratories share price has decreased by 7.7% and in the last one year, it has decreased by 9.64%. The 52-week low for Dr Reddys Laboratories share price was Rs. 1101 and 52-week high was Rs. 1414.9.
Registered Office
8-2-337 Road No 3, Banjara Hills, Hyderabad, Telangana, 500034
Tel No. 91-40-49002900
Email shares:drreddys.com; mail:drreddys.com
Registrars
Bigshare Services Pvt Ltd
Tel No. 91-40-23374967
Email bsshyd:bigshareonlin
Management
Independent Non Exe. Director
Independent Non Exe. Director
Co-Chairman & Managing Director
CS / CO / Head - CSR
Chairman & Exec. Director
Independent Non Exe. Director
Independent Non Exe. Director
Independent Non Exe. Director
Independent Non Exe. Director
Independent Non Exe. Director
Independent Non Exe. Director
Independent Non Exe. Director
Listing Info
500124
DRREDDY
INE089A01031
Jul
Dr Reddys Laboratories Ltd FAQs
You can buy Dr Reddys Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Dr Reddys Laboratories Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 18, 2026 03:59 PM the closing price of Dr Reddys Laboratories Ltd was Rs.1,185.00.
The latest PE ratio of Dr Reddys Laboratories Ltd as of Sep 18, 2026 03:59 PM is 30.71
The latest PB ratio of Dr Reddys Laboratories Ltd as of Sep 18, 2026 03:59 PM is 2.60
The 52-week high of Dr Reddys Laboratories Ltd share price is Rs. 1,414.90 while the 52-week low is Rs. 1,101.00
According to analyst recommendations, Dr Reddys Laboratories Ltd Share has a "Buy" rating for the long term.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 18, 2026 03:59 PM, the market cap of Dr Reddys Laboratories Ltd stood at Rs. 98,909.11 Cr.
Market Outlook
View allNo news to display.
